NTRK2 (Neurotrophic Receptor Tyrosine Kinase 2) encodes TrkB (Tropomyosin receptor kinase B), the primary high-affinity receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4). TrkB is a receptor tyrosine kinase critical for synaptic plasticity, memory formation, learning, and neuronal survival. The BDNF/TrkB signaling pathway is one of the most important neurotrophic systems in the brain and has been strongly implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, Huntington's disease, depression, and various other neurological and psychiatric disorders. The pathway's central role in neural plasticity, cognition, and neuronal survival makes it a high-priority therapeutic target.
Gene SymbolNTRK2
Full NameNeurotrophic Receptor Tyrosine Kinase 2 (TrkB)
Chromosomal Location9q21.33
Associated Diseases[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntington-disease), [Depression](/diseases/depression), [Anxiety](/diseases/anxiety-disorder)
NTRK2 Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, synaptic plasticity, and neuronal survival. TrkB is a member of the tropomyosin receptor kinase (Trk) family, which includes TrkA (NTRK1), TrkB (NTRK2), and TrkC (NTRK3). Each Trk receptor has distinct ligand specificity: TrkB primarily binds BDNF and NT-4, while also being able to respond to NT-3 at lower affinity.
TrkB is expressed in both the developing and adult nervous system, where it supports neuronal survival, process outgrowth, synapse formation, and plasticity. In the adult brain, TrkB signaling is crucial for cognitive functions including learning and memory. The pathway is dynamically regulated, with activity-dependent release of BDNF playing a key role in modulating synaptic strength and structure.
Dysregulation or mutations in this gene contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
NTRK2 encodes TrkB (Tropomyosin receptor kinase B), the primary receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4). TrkB is a receptor tyrosine kinase critical for synaptic plasticity, memory formation, and neuronal survival.
TrkB signaling involves multiple downstream pathways:
- PLC-γ Pathway: Phospholipase C-gamma activation leads to IP3/DAG signaling and calcium release. This pathway regulates synaptic plasticity and gene expression
- PI3K/Akt Pathway: Promotes cell survival through Akt phosphorylation, inhibiting pro-apoptotic proteins. Critical for neuronal survival
- RAS/MAPK Pathway: Regulates gene expression, cell differentiation, synaptic plasticity, and long-term memory formation
- cAMP/PKA Pathway: Modulates ion channel function and gene transcription
The BDNF/TrkB pathway is central to activity-dependent synaptic plasticity:
- Long-term Potentiation (LTP): BDNF release during high-frequency stimulation activates TrkB, enhancing glutamate receptor function and spine growth
- Long-term Depression (LTD): TrkB signaling also contributes to LTD, depending on the context and receptor isoform
- Synaptic Strength: TrkB activation modulates the strength of both excitatory and inhibitory synapses
- Spine Morphogenesis: TrkB signaling promotes the formation and maintenance of dendritic spines
TrkB provides critical neurotrophic support for specific neuronal populations:
- Central Nervous System: Supports cortical and hippocampal neurons, basal forebrain cholinergic neurons, and dopaminergic neurons
- Peripheral Nervous System: Supports sensory and sympathetic neurons
- Activity-Dependent Survival: Neuronal activity that leads to BDNF release promotes survival
TrkB exists in multiple isoforms:
- Full-length TrkB (TrkB-FL): Contains the intracellular tyrosine kinase domain, mediates all canonical TrkB signaling
- Truncated TrkB (TrkB-T1/T2): Lacks the kinase domain, acts as a dominant negative or BDNF scavenger, regulates TrkB signaling
The BDNF/TrkB pathway has complex roles in AD:
- Neuroprotection: BDNF/TrkB signaling can protect neurons from amyloid-beta toxicity, oxidative stress, and excitotoxicity
- Synaptic Dysfunction: Reduced TrkB signaling contributes to synaptic loss and cognitive decline in AD
- BDNF Levels: Altered BDNF levels in AD brains correlate with disease severity
- Therapeutic Potential: Enhancing TrkB signaling is a therapeutic strategy being actively explored
TrkB signaling has important implications for PD:
- Dopaminergic Neuron Survival: BDNF/TrkB signaling supports the survival of dopaminergic neurons in the substantia nigra
- Therapeutic Challenge: While BDNF delivery has been explored as a neuroprotective strategy, achieving adequate delivery to the brain remains challenging
- LRRK2 Connection: Some evidence links LRRK2 mutations to altered TrkB signaling
The BDNF/TrkB pathway is critically involved in HD:
- BDNF Deficiency: HD is associated with reduced BDNF levels, contributing to striatal neuron degeneration
- TrkB Signaling: Maintaining TrkB signaling is protective in HD models
- Therapeutic Target: Enhancing BDNF/TrkB signaling is a major therapeutic strategy for HD
¶ Depression and Mood Disorders
TrkB signaling is strongly implicated in depression:
- Antidepressant Effects: Many antidepressant treatments increase BDNF expression and TrkB signaling
- Psychedelic Mechanism: Recent research shows psychedelic compounds promote plasticity through direct TrkB binding
- Therapeutic Targeting: TrkB agonists represent novel antidepressant strategies
NTRK2 mutations are associated with:
- Intellectual Disability: Some NTRK2 mutations cause neurodevelopmental disorders
- Autism Spectrum Disorder: Altered TrkB signaling may contribute to ASD
TrkB is expressed throughout the nervous system:
- Hippocampus - CA1-CA3 pyramidal neurons and dentate gyrus granule cells
- Cerebral cortex - layers II-III, V-VI, particularly in excitatory neurons
- Basal forebrain - cholinergic neurons projecting to hippocampus and cortex
- Striatum - medium spiny neurons
- Substantia nigra pars compacta - dopaminergic neurons
- Cerebellum - Purkinje cells
- Dorsal root ganglia
- Peripheral nerves
The widespread expression of TrkB in limbic system and reward pathways explains its role in learning, memory, and mood.
¶ Structure and Biochemistry
TrkB is a receptor tyrosine kinase with characteristic structure:
- Extracellular Domain: Contains leucine-rich repeats and immunoglobulin-like domains that bind BDNF and NT-4 with high affinity
- Transmembrane Domain: Single pass transmembrane helix
- Intracellular Domain: Tyrosine kinase domain that initiates downstream signaling cascades upon ligand binding
The receptor undergoes dimerization upon ligand binding, followed by autophosphorylation and recruitment of downstream signaling adaptors.
TrkB represents a high-priority therapeutic target:
- BDNF Mimetics: Small molecules that activate TrkB
- TrkB Agonists: Direct TrkB activating compounds
- Allosteric Modulators: Compounds that enhance TrkB signaling
- Blood-Brain Barrier: Delivery to the brain remains challenging
- Side Effects: Systemic TrkB activation can cause adverse effects
- Isoform Specificity: Targeting specific TrkB isoforms may improve specificity
- Psychedelics: Direct TrkB binding may underlie rapid antidepressant effects
- Gene Therapy: Viral delivery of BDNF or TrkB
- Cell-Penetrant Peptides: Peptide-based TrkB activators
- The trkB tyrosine protein kinase encodes a receptor for BDNF - Klein R, et al. Cell (1989). PMID:2535250
- TrkB signaling in cortical development and function - Huang EJ, et al. Ann Neurol (2001). PMID:11726961
- Neurotrophins in Huntington's disease - Zuccato C, et al. Mech Ageing Dev (2011). PMID:21195753
- Psychedelics Promote Structural and Functional Neural Plasticity - Ly C, et al. Cell Rep (2018). PMID:29898390
- Psychedelics promote plasticity by directly binding to TrkB - Moliner R, et al. Nat Neurosci (2023). PMID:37280397
- Glioma synapses recruit mechanisms of adaptive plasticity - Taylor KR, et al. Nature (2023). PMID:37914930
- Enhanced ERK activity extends ketamine's antidepressant effects - Ma ZZ, et al. Science (2025). PMID:40339008
- BDNF/TrkB signaling in Alzheimer's disease - Perez EJ, et al. Prog Neuropsychopharmacol Biol Psychiatry (2020). PMID:32112906
- Klein R, et al. The trkB tyrosine protein kinase (1989)
- Huang EJ, et al. TrkB signaling in cortical development (2001)
- Zuccato C, et al. Neurotrophins in Huntington's disease (2011)
- Ly C, et al. Psychedelics promote neural plasticity (2018)
- Taylor KR, et al. Glioma synapses and plasticity (2023)
- Fatt MP, et al. Morphine-responsive neurons (2024)
- Moliner R, et al. Psychedelics bind to TrkB (2023)
- Ma ZZ, et al. ERK activity and ketamine (2025)
- Geoffroy H, et al. BDNF signaling in addiction (2017)
- Ye W, et al. Association of NTRK2 with suicidality (2024)
- Clark VD, et al. Hyperfibrinogenemia-mediated astrocyte activation (2018)
- Perez EJ, et al. BDNF/TrkB in AD (2020)
- Luo L, et al. TrkB activation and excitotoxicity (2019)
- Mowrey WR, et al. TrkB agonists for neurological disorders (2018)
- Rajagopal R, et al. Epigenetic regulation of BDNF/TrkB (2019)